Proliferative activity of central neurocytoma : Measurement of tumor volume doubling time, MIB-1 staining index and bromodeoxyuridine labeling index
Central neurocytoma is considered to be a benign intracranial neoplasm, but little is known about the biological behavior of this type of tumor. Proliferative activity of central neurocytoma was measured in 10 cases using MIB-1 staining for Ki-67 antigen. The MIB-1 staining value varied from < 0....
Gespeichert in:
| Veröffentlicht in: | Journal of neuro-oncology 1997-04, Vol.32 (2), p.103-109 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 109 |
|---|---|
| container_issue | 2 |
| container_start_page | 103 |
| container_title | Journal of neuro-oncology |
| container_volume | 32 |
| creator | FUJIMAKI, T MATSUNO, A SASAKI, T TOYODA, T MATSUURA, R OGAI, M KITANAKA, C ASAI, A MATSUTANI, M KIRINO, T |
| description | Central neurocytoma is considered to be a benign intracranial neoplasm, but little is known about the biological behavior of this type of tumor. Proliferative activity of central neurocytoma was measured in 10 cases using MIB-1 staining for Ki-67 antigen. The MIB-1 staining value varied from < 0.1% to 5.6%, to indicating that some of these tumors have proliferative potential similar to that of anaplastic astrocytoma or malignant meningioma. The bromodeoxyuridine labeling index (BUdR LI, BrdU LI) was measured in 2 cases and the results correlated well with those of the MIB-1 analysis. Tumor volume doubling time (Td) measured in one case was 358 days which is similar to that of malignant meningioma. In one case, the MIB-1 value taken before and after 58 Gy of radiation treatment decreased markedly from 5.6% to 0.2%. The other 9 cases were also treated by radiation therapy (50-60 Gy) and no tumor recurrence was observed during follow-up periods ranging from 23 to 160 months. Another two patients with partially removed and 3 with subtotally removed tumors showing relatively high MIB-1 values might also have benefited from radiation therapy. |
| doi_str_mv | 10.1023/A:1005740205113 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_78838614</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2389523546</sourcerecordid><originalsourceid>FETCH-LOGICAL-c309t-48843720733d92917dd899408bcee5c80e690eb9e7361cf0fbb1332524410de03</originalsourceid><addsrcrecordid>eNpd0E1rFTEUBuAgSr1W166EgMWVo8mczCTprhY_Ci26UHA3ZJIzkpJJaj5K7__wBzvFSxeuXjjvw-FwCHnJ2TvOenh_dsoZG6RgPRs4h0dkxwcJnQQJj8mO8VF2gxY_n5JnpVwzxoQEfkSONN886B358y2n4BfMpvpbpMZu4euepoVajDWbQCO2nOy-ptXQU3qFprSM61beo9rWlOltCm1F6lKbg4-_aPUrvqVXFx86Tks1Pt4PfXR4R010dM5pTQ7T3b5l73xEGsyM4QE9J08WEwq-OOQx-fHp4_fzL93l188X52eXnQWmayeUEiB7JgGc7jWXzimtBVOzRRysYjhqhrNGCSO3C1vmmQP0Qy8EZw4ZHJM3__be5PS7YanT6ovFEEzE1MoklQI1crHB1__B69Ry3G6belB66GEQ46ZeHVSbV3TTTfaryfvp8OytPzn0plgTlmyi9eWB9cMolRTwF0KBjtw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2389523546</pqid></control><display><type>article</type><title>Proliferative activity of central neurocytoma : Measurement of tumor volume doubling time, MIB-1 staining index and bromodeoxyuridine labeling index</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>FUJIMAKI, T ; MATSUNO, A ; SASAKI, T ; TOYODA, T ; MATSUURA, R ; OGAI, M ; KITANAKA, C ; ASAI, A ; MATSUTANI, M ; KIRINO, T</creator><creatorcontrib>FUJIMAKI, T ; MATSUNO, A ; SASAKI, T ; TOYODA, T ; MATSUURA, R ; OGAI, M ; KITANAKA, C ; ASAI, A ; MATSUTANI, M ; KIRINO, T</creatorcontrib><description>Central neurocytoma is considered to be a benign intracranial neoplasm, but little is known about the biological behavior of this type of tumor. Proliferative activity of central neurocytoma was measured in 10 cases using MIB-1 staining for Ki-67 antigen. The MIB-1 staining value varied from < 0.1% to 5.6%, to indicating that some of these tumors have proliferative potential similar to that of anaplastic astrocytoma or malignant meningioma. The bromodeoxyuridine labeling index (BUdR LI, BrdU LI) was measured in 2 cases and the results correlated well with those of the MIB-1 analysis. Tumor volume doubling time (Td) measured in one case was 358 days which is similar to that of malignant meningioma. In one case, the MIB-1 value taken before and after 58 Gy of radiation treatment decreased markedly from 5.6% to 0.2%. The other 9 cases were also treated by radiation therapy (50-60 Gy) and no tumor recurrence was observed during follow-up periods ranging from 23 to 160 months. Another two patients with partially removed and 3 with subtotally removed tumors showing relatively high MIB-1 values might also have benefited from radiation therapy.</description><identifier>ISSN: 0167-594X</identifier><identifier>EISSN: 1573-7373</identifier><identifier>DOI: 10.1023/A:1005740205113</identifier><identifier>PMID: 9120539</identifier><identifier>CODEN: JNODD2</identifier><language>eng</language><publisher>Dordrecht: Springer</publisher><subject>2-Methylisoborneol ; Adult ; Antibodies, Monoclonal ; Astrocytoma ; Biological and medical sciences ; Brain diseases ; Brain Neoplasms - diagnostic imaging ; Brain Neoplasms - pathology ; Brain Neoplasms - radiotherapy ; Bromodeoxyuridine ; Cell Division ; Female ; Humans ; Ki-67 Antigen - immunology ; Magnetic Resonance Imaging ; Male ; Medical sciences ; Meningioma ; Neurocytoma - diagnostic imaging ; Neurocytoma - pathology ; Neurocytoma - radiotherapy ; Neurology ; Radiation therapy ; Staining and Labeling ; Tomography, X-Ray Computed ; Tumors ; Tumors of the nervous system. Phacomatoses</subject><ispartof>Journal of neuro-oncology, 1997-04, Vol.32 (2), p.103-109</ispartof><rights>1997 INIST-CNRS</rights><rights>Kluwer Academic Publishers 1997.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c309t-48843720733d92917dd899408bcee5c80e690eb9e7361cf0fbb1332524410de03</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2567874$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9120539$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>FUJIMAKI, T</creatorcontrib><creatorcontrib>MATSUNO, A</creatorcontrib><creatorcontrib>SASAKI, T</creatorcontrib><creatorcontrib>TOYODA, T</creatorcontrib><creatorcontrib>MATSUURA, R</creatorcontrib><creatorcontrib>OGAI, M</creatorcontrib><creatorcontrib>KITANAKA, C</creatorcontrib><creatorcontrib>ASAI, A</creatorcontrib><creatorcontrib>MATSUTANI, M</creatorcontrib><creatorcontrib>KIRINO, T</creatorcontrib><title>Proliferative activity of central neurocytoma : Measurement of tumor volume doubling time, MIB-1 staining index and bromodeoxyuridine labeling index</title><title>Journal of neuro-oncology</title><addtitle>J Neurooncol</addtitle><description>Central neurocytoma is considered to be a benign intracranial neoplasm, but little is known about the biological behavior of this type of tumor. Proliferative activity of central neurocytoma was measured in 10 cases using MIB-1 staining for Ki-67 antigen. The MIB-1 staining value varied from < 0.1% to 5.6%, to indicating that some of these tumors have proliferative potential similar to that of anaplastic astrocytoma or malignant meningioma. The bromodeoxyuridine labeling index (BUdR LI, BrdU LI) was measured in 2 cases and the results correlated well with those of the MIB-1 analysis. Tumor volume doubling time (Td) measured in one case was 358 days which is similar to that of malignant meningioma. In one case, the MIB-1 value taken before and after 58 Gy of radiation treatment decreased markedly from 5.6% to 0.2%. The other 9 cases were also treated by radiation therapy (50-60 Gy) and no tumor recurrence was observed during follow-up periods ranging from 23 to 160 months. Another two patients with partially removed and 3 with subtotally removed tumors showing relatively high MIB-1 values might also have benefited from radiation therapy.</description><subject>2-Methylisoborneol</subject><subject>Adult</subject><subject>Antibodies, Monoclonal</subject><subject>Astrocytoma</subject><subject>Biological and medical sciences</subject><subject>Brain diseases</subject><subject>Brain Neoplasms - diagnostic imaging</subject><subject>Brain Neoplasms - pathology</subject><subject>Brain Neoplasms - radiotherapy</subject><subject>Bromodeoxyuridine</subject><subject>Cell Division</subject><subject>Female</subject><subject>Humans</subject><subject>Ki-67 Antigen - immunology</subject><subject>Magnetic Resonance Imaging</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Meningioma</subject><subject>Neurocytoma - diagnostic imaging</subject><subject>Neurocytoma - pathology</subject><subject>Neurocytoma - radiotherapy</subject><subject>Neurology</subject><subject>Radiation therapy</subject><subject>Staining and Labeling</subject><subject>Tomography, X-Ray Computed</subject><subject>Tumors</subject><subject>Tumors of the nervous system. Phacomatoses</subject><issn>0167-594X</issn><issn>1573-7373</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNpd0E1rFTEUBuAgSr1W166EgMWVo8mczCTprhY_Ci26UHA3ZJIzkpJJaj5K7__wBzvFSxeuXjjvw-FwCHnJ2TvOenh_dsoZG6RgPRs4h0dkxwcJnQQJj8mO8VF2gxY_n5JnpVwzxoQEfkSONN886B358y2n4BfMpvpbpMZu4euepoVajDWbQCO2nOy-ptXQU3qFprSM61beo9rWlOltCm1F6lKbg4-_aPUrvqVXFx86Tks1Pt4PfXR4R010dM5pTQ7T3b5l73xEGsyM4QE9J08WEwq-OOQx-fHp4_fzL93l188X52eXnQWmayeUEiB7JgGc7jWXzimtBVOzRRysYjhqhrNGCSO3C1vmmQP0Qy8EZw4ZHJM3__be5PS7YanT6ovFEEzE1MoklQI1crHB1__B69Ry3G6belB66GEQ46ZeHVSbV3TTTfaryfvp8OytPzn0plgTlmyi9eWB9cMolRTwF0KBjtw</recordid><startdate>19970401</startdate><enddate>19970401</enddate><creator>FUJIMAKI, T</creator><creator>MATSUNO, A</creator><creator>SASAKI, T</creator><creator>TOYODA, T</creator><creator>MATSUURA, R</creator><creator>OGAI, M</creator><creator>KITANAKA, C</creator><creator>ASAI, A</creator><creator>MATSUTANI, M</creator><creator>KIRINO, T</creator><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>19970401</creationdate><title>Proliferative activity of central neurocytoma : Measurement of tumor volume doubling time, MIB-1 staining index and bromodeoxyuridine labeling index</title><author>FUJIMAKI, T ; MATSUNO, A ; SASAKI, T ; TOYODA, T ; MATSUURA, R ; OGAI, M ; KITANAKA, C ; ASAI, A ; MATSUTANI, M ; KIRINO, T</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c309t-48843720733d92917dd899408bcee5c80e690eb9e7361cf0fbb1332524410de03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><topic>2-Methylisoborneol</topic><topic>Adult</topic><topic>Antibodies, Monoclonal</topic><topic>Astrocytoma</topic><topic>Biological and medical sciences</topic><topic>Brain diseases</topic><topic>Brain Neoplasms - diagnostic imaging</topic><topic>Brain Neoplasms - pathology</topic><topic>Brain Neoplasms - radiotherapy</topic><topic>Bromodeoxyuridine</topic><topic>Cell Division</topic><topic>Female</topic><topic>Humans</topic><topic>Ki-67 Antigen - immunology</topic><topic>Magnetic Resonance Imaging</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Meningioma</topic><topic>Neurocytoma - diagnostic imaging</topic><topic>Neurocytoma - pathology</topic><topic>Neurocytoma - radiotherapy</topic><topic>Neurology</topic><topic>Radiation therapy</topic><topic>Staining and Labeling</topic><topic>Tomography, X-Ray Computed</topic><topic>Tumors</topic><topic>Tumors of the nervous system. Phacomatoses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>FUJIMAKI, T</creatorcontrib><creatorcontrib>MATSUNO, A</creatorcontrib><creatorcontrib>SASAKI, T</creatorcontrib><creatorcontrib>TOYODA, T</creatorcontrib><creatorcontrib>MATSUURA, R</creatorcontrib><creatorcontrib>OGAI, M</creatorcontrib><creatorcontrib>KITANAKA, C</creatorcontrib><creatorcontrib>ASAI, A</creatorcontrib><creatorcontrib>MATSUTANI, M</creatorcontrib><creatorcontrib>KIRINO, T</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of neuro-oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>FUJIMAKI, T</au><au>MATSUNO, A</au><au>SASAKI, T</au><au>TOYODA, T</au><au>MATSUURA, R</au><au>OGAI, M</au><au>KITANAKA, C</au><au>ASAI, A</au><au>MATSUTANI, M</au><au>KIRINO, T</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Proliferative activity of central neurocytoma : Measurement of tumor volume doubling time, MIB-1 staining index and bromodeoxyuridine labeling index</atitle><jtitle>Journal of neuro-oncology</jtitle><addtitle>J Neurooncol</addtitle><date>1997-04-01</date><risdate>1997</risdate><volume>32</volume><issue>2</issue><spage>103</spage><epage>109</epage><pages>103-109</pages><issn>0167-594X</issn><eissn>1573-7373</eissn><coden>JNODD2</coden><abstract>Central neurocytoma is considered to be a benign intracranial neoplasm, but little is known about the biological behavior of this type of tumor. Proliferative activity of central neurocytoma was measured in 10 cases using MIB-1 staining for Ki-67 antigen. The MIB-1 staining value varied from < 0.1% to 5.6%, to indicating that some of these tumors have proliferative potential similar to that of anaplastic astrocytoma or malignant meningioma. The bromodeoxyuridine labeling index (BUdR LI, BrdU LI) was measured in 2 cases and the results correlated well with those of the MIB-1 analysis. Tumor volume doubling time (Td) measured in one case was 358 days which is similar to that of malignant meningioma. In one case, the MIB-1 value taken before and after 58 Gy of radiation treatment decreased markedly from 5.6% to 0.2%. The other 9 cases were also treated by radiation therapy (50-60 Gy) and no tumor recurrence was observed during follow-up periods ranging from 23 to 160 months. Another two patients with partially removed and 3 with subtotally removed tumors showing relatively high MIB-1 values might also have benefited from radiation therapy.</abstract><cop>Dordrecht</cop><pub>Springer</pub><pmid>9120539</pmid><doi>10.1023/A:1005740205113</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0167-594X |
| ispartof | Journal of neuro-oncology, 1997-04, Vol.32 (2), p.103-109 |
| issn | 0167-594X 1573-7373 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_78838614 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | 2-Methylisoborneol Adult Antibodies, Monoclonal Astrocytoma Biological and medical sciences Brain diseases Brain Neoplasms - diagnostic imaging Brain Neoplasms - pathology Brain Neoplasms - radiotherapy Bromodeoxyuridine Cell Division Female Humans Ki-67 Antigen - immunology Magnetic Resonance Imaging Male Medical sciences Meningioma Neurocytoma - diagnostic imaging Neurocytoma - pathology Neurocytoma - radiotherapy Neurology Radiation therapy Staining and Labeling Tomography, X-Ray Computed Tumors Tumors of the nervous system. Phacomatoses |
| title | Proliferative activity of central neurocytoma : Measurement of tumor volume doubling time, MIB-1 staining index and bromodeoxyuridine labeling index |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T16%3A49%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Proliferative%20activity%20of%20central%20neurocytoma%20:%20Measurement%20of%20tumor%20volume%20doubling%20time,%20MIB-1%20staining%20index%20and%20bromodeoxyuridine%20labeling%20index&rft.jtitle=Journal%20of%20neuro-oncology&rft.au=FUJIMAKI,%20T&rft.date=1997-04-01&rft.volume=32&rft.issue=2&rft.spage=103&rft.epage=109&rft.pages=103-109&rft.issn=0167-594X&rft.eissn=1573-7373&rft.coden=JNODD2&rft_id=info:doi/10.1023/A:1005740205113&rft_dat=%3Cproquest_pubme%3E2389523546%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2389523546&rft_id=info:pmid/9120539&rfr_iscdi=true |